stockrow
Saturday 7 November 2026
Export JUNS’s income statement to Excel — free account
Jupiter Neurosciences, Inc.
JUNS Healthcare Biotechnology
Jupiter Neurosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21,800.00, down 90.7% from fiscal 2022.
- EPS
- +22.5%
- Free cash flow
- −177.1%
Quarter to June 2026, against a year earlier
2.27
0.14
+6.57%
Follow JUNS
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
P/E ratio |
0.00 | — | — | 0.00 |
P/S ratio |
0.00 | — | — | 0.00 |
Altman Z-Score |
(11.70) | — | — | — |
P/FCF ratio |
0.00 | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(34.36) | — | — | (558.55) |
P/Operating CF |
(14.88) | — | — | (3,994.75) |
P/B ratio |
0.00 | — | — | 0.00 |
Price to Tangible BV |
0.00 | — | — | 0.00 |
EV/Sales |
0.00 | — | — | 0.00 |
EV/EBITDA |
0.00 | — | — | 0.00 |
EV/Operating CF |
(5.83) | — | — | (452.44) |
EV/FCF |
(5.83) | — | — | (452.44) |
Quick Ratio |
0.51 | 1.88 | 0.00 | 0.01 |
Current Ratio |
0.65 | 2.31 | 0.01 | 0.01 |
Net Debt/EBITDA |
0.43 | 1.24 | (0.02) | 0.02 |
Debt/Assets |
0.00% | 0.00% | 71.80% | 0.00% |
Debt/Equity |
0.00 | 0.00 | (0.02) | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.63 | 1.60 | 0.10 | 0.25 |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(134.98) | (12.44) | (17.70) | (4.63) |
| (738.85%) | 299.45% | 73.91% | 0.00% | |
| (146.94%) | (76.83%) | (2,488.27%) | 0.00% | |
ROIC |
0.00% | (480.02%) | 0.00% | 0.00% |
Return on Tangible Assets |
336.26% | (92.37%) | 83.29% | 68.94% |
Average Days of Receivables |
43.53 | — | — | 0.00 |
Research and Development Expense of Revenue |
9,571.56% | 0.00% | 0.00% | 404.11% |
Selling, General and Administrative Expense of Revenue |
31,374.77% | 0.00% | 0.00% | 1,167.12% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
11,094.04% | 0.00% | 0.00% | 323.53% |
Graham Net Nets |
(0.07) | — | — | (0.03) |
Graham Number |
41.83 | — | — | 0.00 |
Earnings Yield |
(25.55%) | — | — | (1.82%) |
Free Cash Flow Yield |
(15.36%) | — | — | (0.22%) |
Revenue per Share |
0.05 | 0.00 | 0.00 | 0.69 |
Operating CF per Share |
(11.75) | (10.22) | (1.37) | (3.69) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(11.75) | (10.22) | (1.37) | (3.69) |
Cash per Share |
8.23 | 9.85 | 0.08 | 0.19 |
Shareholders Equity per Share |
(3.98) | 10.90 | (16.52) | (21.11) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(3.98) | 10.90 | (16.52) | (21.11) |
Free Cash Flow |
(5.41) | (3.91) | (0.48) | (1.25) |
Working Capital |
(2.57) | 2.64 | (5.74) | (7.19) |
Net Current Asset Value |
(2.57) | 2.62 | (5.92) | (7.31) |
EV/EBIT |
0.00 | — | — | 0.00 |
Capex to Sales |
0.00 | — | — | 0.00 |
Price to Operating Income |
0.00 | — | — | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(276.58%) | (49.25%) | 8.49% | 17.63% |
Accounts Receivable Turnover |
0.00 | — | — | 0.00 |
Accounts Payable Turnover |
0.01 | 0.00 | 0.00 | — |
Inventory Turnover |
0.00 | — | — | — |
Average Days of Payables |
55,497.38 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
13,887.38 | — | — | — |
Average Payables |
0.52 | 0.47 | 0.54 | — |
Average Assets |
5.88 | 3.18 | 0.19 | — |
Average Common Equity |
1.17 | (0.81) | (6.47) | — |
Columns are period end dates